Headache

atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

Retrieved on: 
Wednesday, March 27, 2024
Depression, Headache, Atypical depression, Data analysis, Patient, Aes, Trial of the century, Nausea, TRD, Treatment, Safety, Vomiting, Pharmaceutical industry

The open-label Phase 2a study investigated the safety, tolerability and efficacy of a single 10mg dose of BPL-003 alongside psychological support in patients with moderate-to-severe TRD who were not taking concomitant antidepressants.

Key Points: 
  • The open-label Phase 2a study investigated the safety, tolerability and efficacy of a single 10mg dose of BPL-003 alongside psychological support in patients with moderate-to-severe TRD who were not taking concomitant antidepressants.
  • Patients were followed for 12 weeks post-dosing, with assessments conducted at multiple points throughout the study.
  • Initial analysis showed that a single dose of BPL-003 induced a rapid antidepressant response2 in 55% of patients on the day after dosing.
  • The positive data from the Phase 2a study is highly encouraging as we await the results of the larger Phase 2b study anticipated later this year.

Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

Retrieved on: 
Tuesday, March 26, 2024
Brain, Disease, Somnolence, Appetite, Partnership, Headache, Visual analogue scale, Patient, Insomnia, EDS, Anxiety, SDX, Doctor of Philosophy, Epworth Sleepiness Scale, Nausea, Clinical trial, Therapy, Safety, Narcolepsy, ESS, IHSS, Idiopathic hypersomnia, Clouding of consciousness, BFS, Food, Pharmaceutical industry

CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind Phase 2 clinical trial (NCT05668754) evaluating the safety and tolerability of KP1077 (serdexmethylphenidate, or SDX) in patients with idiopathic hypersomnia (IH). This proof-of-concept study was not powered to demonstrate statistical significance.   The data gathered for several secondary and exploratory endpoints, including the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS) and Sleep Inertia Visual Analog Scale (SIVAS) will inform the Phase 3 study design.

Key Points: 
  • CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind Phase 2 clinical trial ( NCT05668754 ) evaluating the safety and tolerability of KP1077 (serdexmethylphenidate, or SDX) in patients with idiopathic hypersomnia (IH).
  • The data gathered for several secondary and exploratory endpoints, including the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS) and Sleep Inertia Visual Analog Scale (SIVAS) will inform the Phase 3 study design.
  • The results from the completed Phase 2 trial provide key information for the design of a potentially pivotal Phase 3 trial of KP1077 in patients with IH.
  • The Company plans to request an end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration to seek guidance on the Phase 3 clinical trial design.

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Retrieved on: 
Tuesday, March 26, 2024
Diagnosis, Blood pressure, Efgartigimod alfa, System, Urination, Urinary tract infection, MHLW, Chest pain, Rituximab, Allergy, Disease, Infection, Risk, Headache, Patient, Sore throat, IWG, History, ITP, Chills, Quality of life, Cough, Euronext, Rash, Respiratory tract infection, Splenectomy, Medicine, Skin, Fever, Antibody, Wheeze, Back pain, Shivering, Safety, Pain, Fatigue, Phlegm, Swelling, Food, Autoimmune disease, Nursing

“argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • By reducing circulating autoantibodies, VYVGART is uniquely designed to serve as a precision intervention that targets the underlying disease biology of ITP.
  • ADVANCE successfully met its primary endpoint, demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
  • Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART.

Armanino Introduces Advanced Fund Administration Services to Enhance Private Equity and Real Estate Fund Management

Retrieved on: 
Tuesday, April 9, 2024
Professional Services, Data Management, Technology, Finance, Fintech, Consulting, Accounting, Health, Headache, Growth, Communication, Environment, Trust, Risk, Internal, LLP, NAV, Investment, AFA

Armanino LLP (“Armanino”), a top 20 national accounting and consulting firm, announces the expansion of Armanino’s Fund Administration Services (AFA) to provide comprehensive fund administration solutions to private equity and real estate investment firms–streamlining operations and enhancing investor confidence by integrating cutting-edge technology, expert financial insights, as well as rigorous updated procedures.

Key Points: 
  • Armanino LLP (“Armanino”), a top 20 national accounting and consulting firm, announces the expansion of Armanino’s Fund Administration Services (AFA) to provide comprehensive fund administration solutions to private equity and real estate investment firms–streamlining operations and enhancing investor confidence by integrating cutting-edge technology, expert financial insights, as well as rigorous updated procedures.
  • The ongoing consolidation in the fund administration space only further complicates matters, creating constant change and significant headaches for management teams.
  • “The need for comprehensive, sophisticated fund administration has never been greater,” says Jason Gilbert, Partner and Fund Administration Practice Leader at Armanino.
  • To learn more, or inquire how Armanino’s Fund Administration Services can support you, contact Jason Gilbert here .

Lundbeck to Present Data on Migraine Impact Reduction and Sustained Response with VYEPTI® (eptinezumab-jjmr) at 76th Annual Meeting of the American Academy of Neurology

Retrieved on: 
Tuesday, April 9, 2024
Health, Other Science, General Health, Clinical Trials, Research, Science, Pharmaceutical, Hypersensitivity, Anaphylaxis, Angioedema, Brain, Eptinezumab, Virtual Private LAN Service, Headache, Patient, American Academy, Interview, MD, Neurology, Migraine, Lundbeck, Quality of life, AAN, Abstract, Pharmaceutical industry

These data will be presented during an oral session at the 76th Annual Meeting of the American Academy of Neurology (AAN) taking place in Denver, Colo., and virtually from April 13-18, 2024.

Key Points: 
  • These data will be presented during an oral session at the 76th Annual Meeting of the American Academy of Neurology (AAN) taking place in Denver, Colo., and virtually from April 13-18, 2024.
  • “Our real-world data helps us better understand how individuals are uniquely impacted by migraine beyond monthly headache days.
  • We’re excited to continually partner with the migraine community to raise the bar on preventive treatment expectations.”
    VYEPTI is indicated for the preventive treatment of migraine in adults.
  • The safety and efficacy of VYEPTI has not been evaluated for use in any psychiatric conditions.

GoExceed Accelerates the Value of Data in Latest Release of Solve(X)

Retrieved on: 
Tuesday, April 9, 2024
Mobile, Wireless, Technology, Professional Services, Software, Small Business, Data Analytics, Data Management, Supply Chain Management, Retail, Artificial Intelligence, Data science, Headache, Organization, Data management, Chvátal

GoExceed, a market leader in data management automation software, today unveils the latest iteration of Solve(X)—a cutting-edge platform for automated data and asset management.

Key Points: 
  • GoExceed, a market leader in data management automation software, today unveils the latest iteration of Solve(X)—a cutting-edge platform for automated data and asset management.
  • This release introduces new features that enhance efficiency and maximize the value of mobile spending.
  • The platform’s latest release provides comprehensive tools for managing mobile devices and plans and offers a holistic view of over 1 million cellular connections.
  • “With this latest release of Solve(X) we have expanded the value we deliver clients, providing a cost optimization solution that delivers meaningful efficiency gains,” continued Chvatal.

Cleveland Guardians Gain Competitive Advantage by Selecting Windstream to Modernize its Network Services

Retrieved on: 
Tuesday, April 9, 2024
Sports, Data Management, Technology, Professional Services, Security, Telecommunications, Data Analytics, Software, Artificial Intelligence, Networks, Baseball, Cloud, Organization, Headache, Sport, Environment, Cleveland Guardians, Connect, Radio, MLB, Guardian, Google Cloud Platform, Major League Baseball, Video game

Windstream Enterprise (WE), a leading IT managed services provider, has been selected by the Major League Baseball (MLB) franchise Cleveland Guardians for its managed software-defined wide-area network (SD-WAN) services to achieve a dedicated and simplified cloud network connection.

Key Points: 
  • Windstream Enterprise (WE), a leading IT managed services provider, has been selected by the Major League Baseball (MLB) franchise Cleveland Guardians for its managed software-defined wide-area network (SD-WAN) services to achieve a dedicated and simplified cloud network connection.
  • Guardians’ front office staff, coaches, scouts and players are dispersed among eight locations, including Progressive Field and their affiliated minor league team stadiums.
  • Under their previous network, limited bandwidth was disrupting the team’s ability to disseminate real-time information such as players’ statistics, team performance metrics and videos.
  • “The Guardians are hitting a home run with Windstream solutions, and we’re thrilled about this new partnership.”
    To learn more about cloud-optimized connectivity solutions from Windstream, please visit windstreamenterprise.com .

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Retrieved on: 
Sunday, April 7, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Arrowhead, Principal, Urinary tract infection, JAMA Cardiology, Apolipoprotein C-III, Risk, Headache, Patient, Hypertriglyceridemia, Diarrhea, COVID-19, American College, APOC3, Pancreatitis, Safety, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).
  • Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels.
  • These data were presented in a late-breaking oral presentation today at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) in Atlanta and simultaneously published in the journal JAMA Cardiology .
  • Subjects treated with plozasiran also showed improvements in multiple atherogenic lipid and lipoprotein levels, including remnant cholesterol, HDL-cholesterol, and non-HDL cholesterol.

Mesh Payments Simplifies Guest Travel for Candidates and Contractors with Key Advancements to Its Travel Management Solution

Retrieved on: 
Tuesday, April 9, 2024
Accounting, HR, Travel, Headache, Policy, Chloride, Communication, Mesh, Hotel

NEW YORK, April 9, 2024 /PRNewswire/ -- Mesh Payments , the innovator in global travel and expense management, today announced a new guest travel solution that eliminates the manual and cumbersome process traditionally associated with the booking and reimbursement of candidate and guest travel.

Key Points: 
  • NEW YORK, April 9, 2024 /PRNewswire/ -- Mesh Payments , the innovator in global travel and expense management, today announced a new guest travel solution that eliminates the manual and cumbersome process traditionally associated with the booking and reimbursement of candidate and guest travel.
  • Guest travel is the latest innovation to the Mesh Travel & Expense Management platform, which provides unprecedented efficiency and spend visibility while meeting the rigorous compliance standards of global, multi-entity corporations.
  • Guest travel streamlines travel booking and expenses for contractors, candidates and other guests, allowing them to book their own itineraries and eliminate expense reimbursements.
  • "This is just the beginning of our journey to streamline travel and expense management for companies worldwide."

Caffeine Powder Market to Reach $1,612.1 Million, Globally, by 2032 at 5.5% CAGR: Allied Market Research

Retrieved on: 
Monday, April 8, 2024
Alertness, Health, Fatigue, Headache, Growth, Data, Drink, Migraine, Caffeine, Medicinal plants

WILMINGTON, Del., April 8, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Caffeine Powder Market by Source (Synthetic Caffeine, Natural Caffeine), and Application (Food and Beverages, Pharmaceuticals, Cosmetics and Personal Care, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the "caffeine powder market" was valued at $949.4 million in 2022, and is estimated to reach $1,612.1 million by 2032, growing at a CAGR of 5.5% from 2023 to 2032.

Key Points: 
  • Moreover, caffeine powder offers consumers the flexibility to customize their caffeine intake according to their preferences and needs.
  • In addition, the globalization of the caffeine powder market has led to increased accessibility and availability of products across regions and channels.
  • Furthermore, Europe is home to several prominent pharmaceutical and food industries that utilize caffeine powder in various formulations, further bolstering market growth.
  • With its robust market infrastructure, consumer demand, and regulatory framework, Europe is expected to maintain its leadership position in the global caffeine powder market.